Ownership and insider activity for Hemab Therapeutics Holdings, Inc. Common Stock (COAG): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.
Price
| Price | $43.10 (closing price, November 3, 2026) |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-24 | Walbert Keli | A-Award | 36,000 | $1.3M |
| 2026-09-24 | Walbert Keli |
Balance Sheet (10y)
| Year | 2025 |
|---|---|
| Cash & Equivalents | $88.0M |
| Short-term Investments | $97.5M |
| Receivables | $2.6M |
| Inventory | 0 |
| Total Current Assets | $192.6M |
| Property, Plant & Equipment | $1.7M |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Total Assets | $194.8M |
| Accounts Payable | $5.7M |
| Short-term Debt | 0 |
| Total Current Liabilities | $10.7M |
| Long-term Debt | 0 |
| Total Liabilities | $371.4M |
| Retained Earnings | -$181.9M |
| Total Equity | -$176.6M |
| Total Debt | $1.2M |
| Net Debt | -$184.3M |
| Working Capital | $181.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 35.85 |
Profitability
| Return on Equity | -36.64% |
| Return on Invested Capital | -10.91% |
| Return on Assets | -10.01% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of COAG: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks